<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136864</url>
  </required_header>
  <id_info>
    <org_study_id>CTA-Control-087276</org_study_id>
    <nct_id>NCT00136864</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)</brief_title>
  <official_title>The Impact of Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer: A Prospective Randomized Clinical Trial (PET START Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Ministry of Health and Long Term Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Locally advanced non-small cell lung cancer, NSCLC, (Stage III) is potentially curable with&#xD;
      aggressive combined modality therapy (chemotherapy and radiation). Conventional imaging can&#xD;
      only evaluate gross anatomic abnormalities but functional imaging with positron emission&#xD;
      tomography (PET) may more accurately identify patients who will benefit from aggressive&#xD;
      combined modality therapy.&#xD;
&#xD;
      This prospective randomized clinical trial will enroll 400 patients that have undergone&#xD;
      conventional staging for lung cancer and have been found to have Stage III NSCLC. The&#xD;
      patients will then be randomized to either standard combined modality therapy for Stage III&#xD;
      NSCLC or to PET imaging prior to combined modality therapy with curative intent. Based on the&#xD;
      PET findings, patients will either be suitable for combined modality therapy with curative&#xD;
      intent or not.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage III NSCLC patients upstaged by PET</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of PET on radiation treatment planning</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic ability of PET standard uptake value</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients downstaged by PET</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET Imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET Diagnostic Imaging</intervention_name>
    <description>Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological evidence of NSCLC. Must have documented pathology report&#xD;
             with histology indicated (e.g. squamous, adenocarcinoma, large cell, NSCLC not&#xD;
             otherwise specified).&#xD;
&#xD;
          -  Stage III (mediastinal node positive) NSCLC based on conventional staging (e.g.&#xD;
             computed tomography [CT] scan of chest and upper abdomen, CT or magnetic resonance&#xD;
             imaging [MRI] of brain, bone scan).&#xD;
&#xD;
          -  Suitable for combined modality (chemotherapy and radiation) therapy or radical&#xD;
             radiation therapy or trimodality therapy (chemotherapy, radiation and surgery).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IV NSCLC (by conventional staging).&#xD;
&#xD;
          -  Small cell lung cancer.&#xD;
&#xD;
          -  Poor performance status Eastern Cooperative Oncology Group (ECOG) 3-4.&#xD;
&#xD;
          -  Poor pulmonary function precluding radical radiation therapy (Adequate pulmonary&#xD;
             reserve for radical radiation therapy. Pulmonary function tests should have forced&#xD;
             expiratory volume in 1 second (FEV1) &gt; 1.0 liter or &gt; 40% predicted, diffusing&#xD;
             capacity of the lung for carbon monoxide (DLCO) &gt; 45% and/or predicted contralateral&#xD;
             FEV1 &gt; 800 cc based on quantitative ventilation perfusion lung scan).&#xD;
&#xD;
          -  Significant concurrent medical problems (e.g. uncontrolled diabetes, active cardiac&#xD;
             problems, significant chronic obstructive pulmonary disease).&#xD;
&#xD;
          -  Insulin dependent diabetic where requirements for PET imaging may be problematic.&#xD;
&#xD;
          -  Unable to lie supine for at least 30 minutes in radiation treatment position for&#xD;
             imaging with PET.&#xD;
&#xD;
          -  Failure to provide informed consent.&#xD;
&#xD;
          -  Previous PET scan relating to recent cancer diagnosis prior to entry into study.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Prior thoracic radiation.&#xD;
&#xD;
          -  Prior malignancy within 3 years from randomization (except nonmelanotic skin cancer or&#xD;
             carcinoma in situ of the cervix).&#xD;
&#xD;
          -  Administered more than two cycles of chemotherapy prior to radical radiation therapy&#xD;
             or concurrent chemoradiation (as part of induction or sequential chemotherapy prior to&#xD;
             randomization) for the current malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yee C Ung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark N Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Evans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto-Sunnybrook Odette Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>November 17, 2011</last_update_submitted>
  <last_update_submitted_qc>November 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>PET Scan</keyword>
  <keyword>Non-Small-Cell Lung Carcinoma</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Radiation Oncology</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Oncology</keyword>
  <keyword>Radiation Planning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

